Inside Precision Medicine June 17, 2025
Inside Precision Medicine‘s Editor in Chief Damian Doherty spoke with Sue McPherson, Executive Director, Client Affairs at WuXi AppTec, about her path into toxicology, the evolving needs of sponsors, and what it takes to run successful preclinical programs today.
Damian Doherty: Sue, thank you for joining me. I know you’ve recently referred to moving “Beyond the Magic Bullet” when talking about the evolution of Antibody-Drug Conjugates, or ADCs. Can you elaborate on what you see as the core innovations bringing this vision to life today?
Sue McPherson: Absolutely, Damian. The fundamental idea of a targeted therapy has been around for ages, but realizing that vision in ADCs comes down to molecular precision in three key areas: the antibody, the linker,...
Today's Sponsors
Today's Sponsor